Quality of Life with LUTATHERA® (lutetium [177Lu] oxodotreotide)
Health-related quality of life (HRQoL) was a major secondary endpoint of the phase III NETTER-1 trial. HRQoL was measured using the EORTC QLQ-C30 and GI.NET-21 questionnaires. Time to deterioration in the quality of life (QoL) from baseline was significantly longer in the 177Lu-DOTATATE arm (n=117) vs the control arm (n=114) for several domains (all p≤0.030).1
This slide deck summarises the quality of life data from the NETTER-1 study.